Treatment with the highly selective IDH1 inhibitor ivosidenib led to a complete remission rate of 40%, with an overall survival of nearly 19 months in this group. Daniel Pollyea, MD, MS, shares results from this phase 1 study.
Recent Articles
New Children’s Hospital Coalition Aims to Combat Pandemic-Driven Drug Shortages
Eleven children’s hospitals have teamed up to form The Children’s Hospital Coalition, aimed at mitigating the effects of drug shortages caused by the COVID-19...
Study Finds Children with Down Syndrome Have Higher Risk of AML
Children with Down syndrome have an estimated 150-fold higher risk of developing acute myeloid leukemia (AML) before age five, compared to children without Down...
Biden Administration Proposes New $6.5 Billion Health Research Agency
The U.S. federal government has proposed dedicating $6.5 billion to establish a medical research agency focused on curing cancer, Alzheimer’s, diabetes, and other diseases.
If...
European Commission Approves Selinexor Plus Dexamethasone for Relapsed/Refractory Myeloma
Selinexor, in combination with dexamethasone, has been granted conditional marketing authorization by the European Commission (EC) for the treatment of adult patients with multiple...
FDA Approves Isatuximab-irfc Combination for Relapsed/Refractory Myeloma
Isatuximab-irfc, in combination with carfilzomib and dexamethasone (Isa-Kd), was approved by the U.S. Food and Drug Administration (FDA) on March 31, 2021 for the...
Current Issue
April 2021 Volume 7 Issue 5
This issue examines long-haul COVID-19, central nervous system relapse in non-Hodgkin lymphoma, and more.